GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) stock price target increased to $135.00, released a research note earlier today by Maxim Group
- Updated: April 21, 2017
Displaying a price of $115.82, GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) traded -0.32% lower on the day. The last stock close price is down -4.36% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the date range. GW Pharmaceuticals PLC- ADR has recorded a 50-day average of $121.30 and a two hundred day average of $121.10. Trading volume was down over the average, with 199,372 shares of GWPH changing hands under the typical 319,248
Indicating a possible upside of 0.17%, Maxim Group raised the target of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) to $135.00
See Chart Below
GW Pharmaceuticals PLC- ADR has 52 week low of $74.05 and a 52 week high of $137.88 and has a total market value of $0.
A total of 8 equity analysts have released a ratings update on GWPH. 2 brokers rating the stock a strong buy, 5 analysts rating the company a buy, zero analysts rating the company a hold, zero brokerages rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $139.75.
Brief Synopsis About GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.